Top

Published in:

01-08-2020 | Aprotinin | Original Article

Performance of ^99mTc-aprotinin scintigraphy for diagnosing light chain (AL) cardiac amyloidosis confirmed by endomyocardial biopsy

Authors: Toru Awaya, MD, Ryogo Minamimoto, MD, PhD, Kentaro Iwama, MD, Shuji Kubota, MD, Masatoshi Hotta, MD, Risen Hirai, MD, Masaya Yamamoto, MD, Osamu Okazaki, MD, PhD, Hisao Hara, MD, PhD, Yukio Hiroi, MD, PhD, Michiaki Hiroe, MD, PhD, Masao Moroi, MD, PhD

Published in: Journal of Nuclear Cardiology | Issue 4/2020

Abstract

Background

Light chain (AL) cardiac amyloidosis is associated with a poor prognosis. Diagnosing at an early stage is critical for treatment and the management of cardiac complication.

Purpose

We aimed to evaluate the diagnostic performance of ^99mTc-aprotinin images in patients with AL cardiac amyloidosis.

Methods and Results

^99mTc-aprotinin scintigraphy and endomyocardial biopsy were performed in 10 patients with suspected amyloidosis. Endomyocardial biopsy showed amyloid deposits in 5 of 10 patients. ^99mTc-aprotinin (planer image) was positive in 4 of 5 patients who had amyloid deposits in endomyocardial biopsy. On the other hand, all 5 patients without amyloid deposits were negative in planer image. ^99mTc-aprotinin (SPECT/CT image) was positive in all 5 patients who had amyloid deposits.

Conclusions

^99mTc-aprotinin scintigraphy is valuable for the non-invasive diagnosis of AL cardiac amyloidosis.

Available only for authorised users

Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: A comparison with light chain-associated amyloidosis. Arch Intern Med 2005;165(12):1425-9.PubMed

Venner CP, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012;119(19):4387-90.PubMed

Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30(9):989-95.PubMedPubMedCentral

Milani P, Gertz MA, Merlini G, Dispenzieri A. Attitudes about when and how to treat patients with AL amyloidosis: An international survey. Amyloid 2017;24(4):213-6.PubMed

Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2010;3(2):155-64.PubMed

Hosch W, Kristen AV, Libicher M, Dengler TJ, Aulmann S, Heye T, et al. Late enhancement in cardiac amyloidosis: Correlation of MRI enhancement pattern with histopathological findings. Amyloid 2008;15(3):196-204.PubMed

Hashimura H, Ishibashi-Ueda H, Yonemoto Y, Ohta-Ogo K, Matsuyama TA, Ikeda Y, et al. Late gadolinium enhancement in cardiac amyloidosis: Attributable both to interstitial amyloid deposition and subendocardial fibrosis caused by ischemia. Heart Vessels 2016;31(6):990-5.PubMed

Aprile C, Marinone G, Saponaro R, Bonino C, Merlini G. Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin. Eur J Nucl Med 1995;22(12):1393-401.PubMed

Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013;6(2):195-201.PubMedPubMedCentral

10.

Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation 2012;126(10):1286-300.PubMedPubMedCentral

11.

Han S, Chong V, Murray T, McDonagh T, Hunter J, Poon FW, et al. Preliminary experience of ^99mTc-Aprotinin scintigraphy in amyloidosis. Eur J Haematol 2007;79(6):494-500.PubMed

12.

Minamimoto R, Kubota K, Ishii K, Morooka M, Okasaki M, Miyata Y, et al. Re-evaluating the potentials and limitations of (99m)Tc-aprotinin scintigraphy for amyloid imaging. Am J Nucl Med Mol Imaging 2013;3(3):261-71.PubMedPubMedCentral

13.

Cardoso I, Pereira PJ, Damas AM, Saraiva MJ. Aprotinin binding to amyloid fibrils. Eur J Biochem 2000;267(8):2307-11.PubMed

14.

Smyth DR, Tsopelas C. An improved (99m)Tc-aprotinin kit formulation: Quality control analysis of radiotracer stability and cold kit shelf life. Nucl Med Biol 2005;32(8):885-9.PubMed

15.

Sojan SM, Smyth DR, Tsopelas C, Mudge D, Collins PJ, Chatterton BE. Pharmacokinetics and normal scintigraphic appearance of ^99mTc aprotinin. Nucl Med Commun 2005;26(6):535-9.PubMed

16.

Lee JH, Lee GY, Kim SJ, Kim KH, Jeon ES, Lee KH, et al. Imaging findings and literature review of 18F-FDG PET/CT in primary systemic AL amyloidosis. Nucl Med Mol Imaging 2015;49(3):182-90.PubMedPubMedCentral

17.

Lee SP, Lee ES, Choi H, Im HJ, Koh Y, Lee MH, et al. 11C-Pittsburgh B PET imaging in cardiac amyloidosis. JACC Cardiovasc Imaging 2015;8(1):50-9.PubMed

18.

Garcia-Gonzalez P, Cozar-Santiago MDP, Maceira AM. Cardiac amyloidosis detected using (18)F-florbetapir PET/CT. Rev Esp Cardiol (Engl Ed) 2016;69(12):1215.PubMed

19.

Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 2005;95(4):535-7.PubMed

20.

Bulluck H, Maestrini V, Rosmini S, Abdel-Gadir A, Treibel TA, Castelletti S, et al. Myocardial T1 mapping. Circ J 2015;79(3):487-94.PubMed

21.

Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: Impact on survival outcomes. J Clin Oncol 2012;30(36):4541-9.PubMed

22.

Varr BC, Zarafshar S, Coakley T, Liedtke M, Lafayette RA, Arai S, et al. Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. Heart Rhythm 2014;11(1):158-62.PubMed

23.

Palladini G, Malamani G, Co F, Pistorio A, Recusani F, Anesi E, et al. Holter monitoring in AL amyloidosis: Prognostic implications. Pacing Clin Electrophysiol 2001;24(8 Pt 1):1228-33.PubMed

Title: Performance of 99mTc-aprotinin scintigraphy for diagnosing light chain (AL) cardiac amyloidosis confirmed by endomyocardial biopsy
Authors: Toru Awaya, MD
Ryogo Minamimoto, MD, PhD
Kentaro Iwama, MD
Shuji Kubota, MD
Masatoshi Hotta, MD
Risen Hirai, MD
Masaya Yamamoto, MD
Osamu Okazaki, MD, PhD
Hisao Hara, MD, PhD
Yukio Hiroi, MD, PhD
Michiaki Hiroe, MD, PhD
Masao Moroi, MD, PhD
Publication date: 01-08-2020
Publisher: Springer International Publishing
Keywords: Aprotinin
Cardiac Amyloidosis
ICD Implantation
Scintigraphy
Amyloidosis
AL Amyloidosis
Implantable Cardioverter Defibrillator
Implantable Cardioverter Defibrillator
ICD Implantation
ICD Implantation
Published in: Journal of Nuclear Cardiology / Issue 4/2020
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-019-01868-9

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Performance of ^99mTc-aprotinin scintigraphy for diagnosing light chain (AL) cardiac amyloidosis confirmed by endomyocardial biopsy

Abstract

Background

Purpose

Methods and Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Purpose

Methods and Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2020

Accuracy of cardiac functional parameters measured from gated radionuclide myocardial perfusion imaging in mice

Reproducibility of LVEF, LV volumes, and LV mass between Rubidium-82 PET/CT scans in young healthy volunteers using two commercially available software packages

Cardiac uptake patterns in routine 18F-FDG PET-CT scans: A pictorial review

First comparison of performances between the new whole-body cadmium–zinc–telluride SPECT-CT camera and a dedicated cardiac CZT camera for myocardial perfusion imaging: Analysis of phantom and patients

Correction to: Early nuclear stress testing after CABG: The new standard or too soon to tell?

Correction to: Risk stratification with vasodilator stress SPECT myocardial perfusion imaging in patients with elevated cardiac biomarkers

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page